Trial Profile

A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Alpelisib (Primary) ; Capivasertib (Primary) ; Elacestrant (Primary) ; Everolimus (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ELEVATE
Sponsors Stemline Therapeutics

Most Recent Events

22 May 2025 According to a Menarini media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
18 Feb 2025 Planned End Date changed from 31 Aug 2026 to 28 Dec 2028.
18 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 27 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com